Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kelliher Mike Insider Profile
4 Followers
Kelliher Mike, Director at Capricor Therapeutics, holds ― shares in Capricor Therapeutics (Ticker: CAPR), holds 160.00K shares in Ardelyx (Ticker: ARDX). Most recently, Kelliher Mike ― shares of Capricor Therapeutics on ― for an estimated value of ―.
Kelliher Mike has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kelliher Mike holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kelliher Mike
Kelliher Mike's Trading History
Capricor Therapeutics
―
Director
―
―
Ardelyx
Mar 27, 2024
See Remarks
Uninformative Buy
―
$1.03M
List of latest transactions for each holding click on a transaction to see Kelliher Mike's performance on stock
You May Also Like
Kelliher Mike insider profile FAQ
What is the percentage of profitable transactions made by Kelliher Mike?
The percentage of profitable transactions made by Kelliher Mike is ―.
What is the average return per transaction made by Kelliher Mike?
The average return per transaction made by Kelliher Mike is ―.
What stocks does Kelliher Mike hold?
Kelliher Mike holds: CAPR, ARDX stocks.
What was Kelliher Mike’s latest transaction?
Kelliher Mike latest transaction was an Uninformative Buy of ―.
What was Kelliher Mike's most profitable transaction?
Kelliher Mike’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kelliher Mike's role in Capricor Therapeutics?
Kelliher Mike's role in Capricor Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.